Form 8-K NAVIDEA BIOPHARMACEUTICA For: Feb 17
As previously disclosed, Navidea Biopharmaceuticals, Inc. (“Navidea”) and Beijing Sinotau Medical Research Co., Ltd., a Chinese pharmaceutical company (“Sinotau”) were previously engaged in an ongoing dispute relating to rights for the Tc 99m tilmanocept product in China and other claims.
On February 17, 2018, Navidea entered into a Settlement Agreement and Mutual Release with Sinotau, pursuant to which both companies agreed to stipulate to the voluntarily dismissal of all claims against each other with prejudice. The agreement also contained a mutual release of claims.